It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Bovine tuberculosis is an infectious disease of global significance that remains endemic in many countries. Mycobacterium bovis infection in cattle is characterized by a cell-mediated immune response (CMI) that precedes humoral responses, however the timing and trajectories of CMI and antibody responses determined by newer generation assays remain undefined. Here we used defined-antigen interferon-gamma release assays (IGRA) and an eleven-antigen multiplex ELISA (Enferplex TB test) alongside traditional tuberculin-based IGRA and IDEXX M. bovis antibody tests to assess immune trajectories following experimental M. bovis infection of cattle. The results show CMI responses developed as early as two-weeks post-infection, with all infected cattle testing positive three weeks post-infection. Interestingly, 6 of 8 infected animals were serologically positive with the Enferplex TB assay as early as 4 weeks post-infection. As expected, application of the tuberculin skin test enhanced subsequent serological reactivity. Infrequent M. bovis faecal shedding was observed but was uncorrelated with observed immune trajectories. Together, the results show that early antibody responses to M. bovis infection are detectable in some individuals and highlight an urgent need to identify biomarkers that better predict infection outcomes, particularly for application in low-and-middle income countries where test-and-slaughter based control methods are largely unfeasible.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Animal and Plant Health Agency, Bacteriology, Addlestone, UK (GRID:grid.422685.f) (ISNI:0000 0004 1765 422X)
2 The Pennsylvania State University, The Huck Institutes of Life Sciences, University Park, USA (GRID:grid.29857.31) (ISNI:0000 0001 2097 4281)
3 Enfer Scientific, Unit T, M7 Business Park, Newhall, Naas, Ireland (GRID:grid.422685.f)
4 University of Cambridge, Disease Dynamics Unit, Department of Veterinary Medicine, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000 0001 2188 5934)
5 The Bill & Melinda Gates Foundation, Seattle, USA (GRID:grid.418309.7) (ISNI:0000 0000 8990 8592)
6 The Pennsylvania State University, The Huck Institutes of Life Sciences, University Park, USA (GRID:grid.29857.31) (ISNI:0000 0001 2097 4281); The Pennsylvania State University, Department of Animal Science, University Park, USA (GRID:grid.29857.31) (ISNI:0000 0001 2097 4281)